Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: KRYS

Krystal Biotech, Inc.

Healthcare | Biotechnology

No licensed closing price on file for KRYS. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$7.97

Krystal Biotech, Inc. (NASDAQ: KRYS) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:49 UTC.

What Krystal Biotech, Inc. does

The company is a fully integrated biotechnology firm that discovers, develops, manufactures, and commercializes genetic medicines using an engineered herpes simplex virus-1 platform to treat diseases with high unmet medical needs. The company's proprietary technology delivers therapeutic genes to cells through vectors that can be administered non-invasively or minimally invasively in office or home settings.

Summarized from Krystal Biotech, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$7.97
Return on equity16.80%

Revenue, margins & earnings

FY2023 Revenue: $51M — margin split not shown (non-operating gains)$51MFY2023FY2024 Revenue: $291M — margin split not shown (non-operating gains)$291MFY2024FY2025 Revenue: $389M — margin split not shown (non-operating gains)$389MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-16
  • 2026-09-16DirectorStock Option (Right to Buy)Award1,187—
  • 2026-09-16DirectorStock Option (Right to Buy)Award1,187—
  • 2026-09-16DirectorRestricted Stock UnitsAward471—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Krystal Biotech, Inc. do?

The company is a fully integrated biotechnology firm that discovers, develops, manufactures, and commercializes genetic medicines using an engineered herpes simplex virus-1 platform to treat diseases with high unmet medical needs.

When did KRYS last file with the SEC?

Krystal Biotech, Inc.'s most recent SEC filing on record is a 8-K filed 2026-05-20. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:49 UTC. This page is also available as JSON at /api/data?ticker=KRYS and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for KRYS and 5,000+ tickers.

Create a free account — keep KRYS
For your agent
GET /api/data?ticker=KRYS

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt